The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents

Sonia A Tucci, Emma J Boyland, Jason CG HalfordKissileff Laboratory for the Study of Human Ingestive Behaviour, School of Psychology, University of Liverpool, Liverpool, UKAbstract: Obesity is a global epidemic associated with significant morbidity and mortality in adults and ill health in children....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Tucci S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	lipase amylase saccharidases overweight Orlistat® Alli® digestion body weight Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/9ffcaac81aa04f409f1269757d4f193a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9ffcaac81aa04f409f1269757d4f193a
record_format	dspace
spelling	oai:doaj.org-article:9ffcaac81aa04f409f1269757d4f193a2021-12-02T03:35:24ZThe role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents1178-7007https://doaj.org/article/9ffcaac81aa04f409f1269757d4f193a2010-05-01T00:00:00Zhttps://www.dovepress.com/the-role-of-lipid-and-carbohydrate-digestive-enzyme-inhibitors-in-the--peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Sonia A Tucci, Emma J Boyland, Jason CG HalfordKissileff Laboratory for the Study of Human Ingestive Behaviour, School of Psychology, University of Liverpool, Liverpool, UKAbstract: Obesity is a global epidemic associated with significant morbidity and mortality in adults and ill health in children. A proven successful approach in weight management has been the disruption of nutrient digestion, with orlistat having been used to treat obesity for the last 10 years. Although orlistat-induced weight loss remains modest, it produces meaningful reductions in risk factors for obesity-related conditions such as diabetes and cardiovascular disease. Moreover, this lipase inhibitor is free of the serious side effects that have dogged appetite-suppressing drugs. This success had driven investigation into new generation nutraceuticals, supplements and pharmaceutical agents that inhibit the breakdown of complex carbohydrates and fats within the gut. This review focuses on agents purported to inhibit intestinal enzymes responsible for macronutrient digestion. Except for some synthetic products, the majority of agents reviewed are either botanical extracts or bacterial products. Currently, carbohydrate digestion inhibitors are under development to improve glycemic control and these may also induce some weight loss. However, colonic fermentation induced side effects, such as excess gas production, remain an issue for these compounds. The α-glucosidase inhibitor acarbose, and the α-amylase inhibitor phaseolamine, have been used in humans with some promising results relating to weight loss. Nonetheless, few of these agents have made it into clinical studies and without any clinical proof of concept or proven efficacy it is unlikely any will enter the market soon.Keywords: lipase, amylase, saccharidases, overweight, orlistat, Alli®, digestion, body weightTucci SDove Medical PressarticlelipaseamylasesaccharidasesoverweightOrlistat®Alli®digestionbody weightSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 3, Pp 125-143 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	lipase amylase saccharidases overweight Orlistat® Alli® digestion body weight Specialties of internal medicine RC581-951
spellingShingle	lipase amylase saccharidases overweight Orlistat® Alli® digestion body weight Specialties of internal medicine RC581-951 Tucci S The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
description	Sonia A Tucci, Emma J Boyland, Jason CG HalfordKissileff Laboratory for the Study of Human Ingestive Behaviour, School of Psychology, University of Liverpool, Liverpool, UKAbstract: Obesity is a global epidemic associated with significant morbidity and mortality in adults and ill health in children. A proven successful approach in weight management has been the disruption of nutrient digestion, with orlistat having been used to treat obesity for the last 10 years. Although orlistat-induced weight loss remains modest, it produces meaningful reductions in risk factors for obesity-related conditions such as diabetes and cardiovascular disease. Moreover, this lipase inhibitor is free of the serious side effects that have dogged appetite-suppressing drugs. This success had driven investigation into new generation nutraceuticals, supplements and pharmaceutical agents that inhibit the breakdown of complex carbohydrates and fats within the gut. This review focuses on agents purported to inhibit intestinal enzymes responsible for macronutrient digestion. Except for some synthetic products, the majority of agents reviewed are either botanical extracts or bacterial products. Currently, carbohydrate digestion inhibitors are under development to improve glycemic control and these may also induce some weight loss. However, colonic fermentation induced side effects, such as excess gas production, remain an issue for these compounds. The α-glucosidase inhibitor acarbose, and the α-amylase inhibitor phaseolamine, have been used in humans with some promising results relating to weight loss. Nonetheless, few of these agents have made it into clinical studies and without any clinical proof of concept or proven efficacy it is unlikely any will enter the market soon.Keywords: lipase, amylase, saccharidases, overweight, orlistat, Alli®, digestion, body weight
format	article
author	Tucci S
author_facet	Tucci S
author_sort	Tucci S
title	The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
title_short	The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
title_full	The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
title_fullStr	The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
title_full_unstemmed	The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
title_sort	role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/9ffcaac81aa04f409f1269757d4f193a
work_keys_str_mv	AT tuccis theroleoflipidandcarbohydratedigestiveenzymeinhibitorsinthemanagementofobesityareviewofcurrentandemergingtherapeuticagents AT tuccis roleoflipidandcarbohydratedigestiveenzymeinhibitorsinthemanagementofobesityareviewofcurrentandemergingtherapeuticagents
_version_	1718401748045922304

The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents

Ejemplares similares